Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kinaxo collaborates with Astrazeneca
Under the pact, Kinaxo will make use of high-end mass spectrometry-based technologies to quantitatively evaluate posttranslational protein modifications on a proteome-wide scale. Kinaxo CTO Henrik Daub said that
Under the pact, Kinaxo will make use of high-end mass spectrometry-based technologies to quantitatively evaluate posttranslational protein modifications on a proteome-wide scale. Kinaxo CTO Henrik Daub said that
The original agreement was signed in January 2009 between Santaris Pharma and Wyeth, which was acquired by Pfizer. As per the terms of the extended agreement, Santaris Pharma
As per the terms of the agreement, arGEN-X expects to develop new human monoclonal antibody (mAb) candidates that act on various functional sites on Lilly targets. However, Lilly
Prior to its decision, FDA has completed the review of a submission dated 12 November 2010 which provided a Complete Response to the Agency’s reasons for continuing this
Under the agreement, Servier will pay around $35m as an upfront payment and, approximately $470m of milestone payment and tiered royalties. The agreement gives development and commercialization rights
As per the terms of the agreement, Elis has gained commercialization and marketing rights for Vitaros in the Gulf Countries and part of the Middle East (including, Lebanon,
The blinded, placebo-controlled, escalating-dose will enroll 100 healthy adults 18 to 49 years old, who will be grouped into four cohorts and randomised to receive either vaccine treatment
Under the pact, IDBS will install its Bioprocess Execution System to optimize the management of process development data and drive operational excellence to Lonza customers. According to IDBS,
Almirall and Forest said that Aclidinium was well tolerated in the study and all secondary endpoints demonstrated differences vs placebo for both doses. The Phase III double-blind placebo-controlled
Health Insights’ MedicaPlus is one of the comprehensive Hospital Information Management System applications to be developed in the Middle East. Health Insights’ decision to partner with InterSystems follows